122 related articles for article (PubMed ID: 7549793)
1. Fibroblast growth factors and their specific binding sites in normal urothelium and transitional cell carcinoma (TCC) of the human bladder.
Palcy S; Chopin DK; Caruelle D; Ravery V; Barritault D; Caruelle JP
Cell Mol Biol (Noisy-le-grand); 1995 Jun; 41(4):565-75. PubMed ID: 7549793
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma.
Messing EM
Cancer Res; 1990 Apr; 50(8):2530-7. PubMed ID: 1690599
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828
[TBL] [Abstract][Full Text] [Related]
4. Expression of chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) in bladder transitional cell carcinoma.
Ham WS; Lee JH; Yu HS; Choi YD
Urology; 2008 Oct; 72(4):921-6. PubMed ID: 18387660
[TBL] [Abstract][Full Text] [Related]
5. In vitro changes in plasma membrane heparan sulfate proteoglycans and in perlecan expression participate in the regulation of fibroblast growth factor 2 mitogenic activity.
Guillonneau X; Tassin J; Berrou E; Bryckaert M; Courtois Y; Mascarelli F
J Cell Physiol; 1996 Jan; 166(1):170-87. PubMed ID: 8557766
[TBL] [Abstract][Full Text] [Related]
6. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
[TBL] [Abstract][Full Text] [Related]
7. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor (FGF)-1, FGF2, FGF7 and FGF receptors are uniformly expressed in trophoblast giant cells during restricted trophoblast invasion in cows.
Pfarrer C; Weise S; Berisha B; Schams D; Leiser R; Hoffmann B; Schuler G
Placenta; 2006; 27(6-7):758-70. PubMed ID: 16129484
[TBL] [Abstract][Full Text] [Related]
9. Transient receptor potential vanilloid type 1 (TRPV1) expression changes from normal urothelium to transitional cell carcinoma of human bladder.
Lazzeri M; Vannucchi MG; Spinelli M; Bizzoco E; Beneforti P; Turini D; Faussone-Pellegrini MS
Eur Urol; 2005 Oct; 48(4):691-8. PubMed ID: 15992990
[TBL] [Abstract][Full Text] [Related]
10. [Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof].
Zhou JT; Cai ZM; Li NC; Na YQ
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1970-4. PubMed ID: 17064593
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder.
Suzuki K; Morita T; Tokue A
Int J Urol; 2005 Feb; 12(2):152-8. PubMed ID: 15733109
[TBL] [Abstract][Full Text] [Related]
12. A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma.
Adam RM; Danciu T; McLellan DL; Borer JG; Lin J; Zurakowski D; Weinstein MH; Rajjayabun PH; Mellon JK; Freeman MR
Cancer Res; 2003 Jan; 63(2):484-90. PubMed ID: 12543806
[TBL] [Abstract][Full Text] [Related]
13. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.
Elsamman E; Fukumori T; Kasai T; Nakatsuji H; Nishitani MA; Toida K; Ali N; Kanayama HO
BJU Int; 2006 Jun; 97(6):1202-7. PubMed ID: 16686711
[TBL] [Abstract][Full Text] [Related]
14. Targeting urothelium: ex vivo assay standardization and selection of internalizing ligands.
Ardelt PU; Wood CG; Chen L; Mintz PJ; Moya C; Arap MA; Wright KC; Pasqualini R; Arap W
J Urol; 2003 Apr; 169(4):1535-40. PubMed ID: 12629410
[TBL] [Abstract][Full Text] [Related]
15. Translational studies of glutathione in bladder cancer cell lines and human specimens.
Pendyala L; Velagapudi S; Toth K; Zdanowicz J; Glaves D; Slocum H; Perez R; Huben R; Creaven PJ; Raghavan D
Clin Cancer Res; 1997 May; 3(5):793-8. PubMed ID: 9815751
[TBL] [Abstract][Full Text] [Related]
16. Expression of bcl-2 and bcl-X in bladder cancer.
Kirsh EJ; Baunoch DA; Stadler WM
J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
[TBL] [Abstract][Full Text] [Related]
17. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
18. FGF2 as an autocrine growth factor for immortal human breast epithelial cells.
Souttou B; Hamelin R; Crépin M
Cell Growth Differ; 1994 Jun; 5(6):615-23. PubMed ID: 8086338
[TBL] [Abstract][Full Text] [Related]
19. Identification of survivin, an inhibitor of apoptosis, in canine urinary bladder transitional cell carcinoma.
Rankin WV; Henry CJ; Turnquist SE; Turk JR; Beissenherz ME; Tyler JW; Rucker EB; Knapp DW; Rodriguez CO; Green JA
Vet Comp Oncol; 2008 Sep; 6(3):141-50. PubMed ID: 19178674
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma.
Seargent JM; Loadman PM; Martin SW; Naylor B; Bibby MC; Gill JH
Urology; 2005 Apr; 65(4):815-20. PubMed ID: 15833553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
